Terms: = Endocrine gland cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1
332 results:
1. Randomized Phase II Study of Gemcitabine With or Without atr Inhibitor Berzosertib in Platinum-Resistant Ovarian cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
[TBL] [Abstract] [Full Text] [Related]
2. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.
Hrudka J; Kalinová M; Ciprová V; Moravcová J; Dvořák R; Matěj R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542259
[TBL] [Abstract] [Full Text] [Related]
3. AKTing on R Loops Makes for an atractive Target in Ovarian cancer Therapy.
Ramanarayanan V; Oberdoerffer P
Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
[TBL] [Abstract] [Full Text] [Related]
4. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
5. CKS1B as a potential target for prognostic assessment and intervention in pancreatic cancer and its role in abnormal proliferation and cellular phenotype through mediation of cell cycle signaling pathways.
Tang Y; Lan X; Yan M; Fu Z; Li H
Saudi Med J; 2024 Feb; 45(2):128-138. PubMed ID: 38309745
[TBL] [Abstract] [Full Text] [Related]
6. AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in Ovarian cancer.
Huang TT; Chiang CY; Nair JR; Wilson KM; Cheng K; Lee JM
Cancer Res; 2024 Mar; 84(6):887-904. PubMed ID: 38241710
[TBL] [Abstract] [Full Text] [Related]
7. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
8. Targeted inhibition of the atr/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract] [Full Text] [Related]
9. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract] [Full Text] [Related]
10. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic cancer.
Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
[TBL] [Abstract] [Full Text] [Related]
11. Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian cancer.
Nasioudis D; George EM; Xu H; Kim H; Simpkins F
Cancer Treat Res; 2023; 186():189-206. PubMed ID: 37978137
[TBL] [Abstract] [Full Text] [Related]
12. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic inhibition of atr in differentiated thyroid cancer.
Lin SF; Lee YY; Wu MH; Lu YL; Yeh CN; Chen WY; Chou TC; Wong RJ
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902083
[TBL] [Abstract] [Full Text] [Related]
14. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Park S; Kim YJ; Min YJ; Mortimer PGS; Kim HJ; Smith SA; Dean E; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
Cancer; 2024 Feb; 130(4):541-552. PubMed ID: 37843249
[TBL] [Abstract] [Full Text] [Related]
15. DNA2 Nuclease Inhibition Confers Synthetic Lethality in cancers with Mutant p53 and Synergizes with PARP Inhibitors.
Folly-Kossi H; Graves JD; Garan LAW; Lin FT; Lin WC
Cancer Res Commun; 2023 Oct; 3(10):2096-2112. PubMed ID: 37756561
[TBL] [Abstract] [Full Text] [Related]
16. The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer.
Ren L; Qing X; Wei J; Mo H; Liu Y; Zhi Y; Lu W; Zheng M; Zhang W; Chen Y; Zhang Y; Pan T; Zhong Q; Li R; Zhang X; Ruan X; Yu R; Li J
Cell Death Dis; 2023 Aug; 14(8):568. PubMed ID: 37633920
[TBL] [Abstract] [Full Text] [Related]
17. Outcomes of lung oligometastasis in pancreatic cancer.
Takeda T; Sasaki T; Ichinose J; Inoue Y; Okamoto T; Mie T; Furukawa T; Kasuga A; Oba A; Matsuura Y; Nakao M; Ozaka M; Mun M; Takahashi Y; Sasahira N
Jpn J Clin Oncol; 2023 Dec; 53(12):1144-1152. PubMed ID: 37609670
[TBL] [Abstract] [Full Text] [Related]
18. The differential effect of neoadjuvant chemotherapy and chemoradiation on nodal downstaging in pancreatic adenocarcinoma.
Altimari M; Wells A; Abad J; Chawla A
Pancreatology; 2023 Nov; 23(7):805-810. PubMed ID: 37599170
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
20. Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic cancers with DNA Damage Repair Deficiencies.
Restifo D; McDermott JR; Cvetkovic D; Dos Santos T; Ogier C; Surumbayeva A; Handorf EA; Schimke C; Ma C; Cai KQ; Olszanski AJ; Kathad U; Bhatia K; Sharma P; Kulkarni A; Astsaturov I
Mol Cancer Ther; 2023 Oct; 22(10):1182-1190. PubMed ID: 37552607
[TBL] [Abstract] [Full Text] [Related]
[Next]
